checkAd

    EQS-News  513  0 Kommentare CureVac Announces Voting Results of General Meeting

    Für Sie zusammengefasst
    • CureVac voting results announced
    • Shareholders approve all proposals
    • New appointments and reappointments made

    Issuer: CureVac / Key word(s): AGM/EGM
    CureVac Announces Voting Results of General Meeting

    24.06.2024 / 22:05 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    CureVac Announces Voting Results of General Meeting

     

    TÜBINGEN, Germany/BOSTON, USA – June 24, 2024 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general meeting.

    The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of the Supervisory Board effective June 24th, 2024, and KPMG Accountants N.V. was reappointed as the external auditors for the financial year 2024.

    A table containing tabulations of the votes casted is expected to be released in the coming days.

     

    About CureVac

    CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News CureVac Announces Voting Results of General Meeting Issuer: CureVac / Key word(s): AGM/EGM CureVac Announces Voting Results of General Meeting 24.06.2024 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Voting Results of General Meeting   …

    Schreibe Deinen Kommentar

    Disclaimer